Biocon Biologics gets marketing authorisation from EC for Denosumab Biosimilars Vevzuo and Evfraxy
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a leading global biosimilars company, has received marketing authorisation from the European Commission (EC) for its biosimilars Vevzuo® and Evfraxy®, both referencing Denosumab. This regulatory milestone allows the company to market the two products across the European Union (EU), marking a significant step in its journey to expand its presence in advanced biologics.
Vevzuo® has been approved for the prevention of skeletal-related events in adults suffering from advanced cancers that involve bone, as well as for the treatment of giant cell tumour (GCT) of bone in adults and skeletally mature adolescents. On the other hand, Evfraxy® has been cleared for a broader range of uses in bone health, including the treatment of osteoporosis in men and postmenopausal women. It is also authorised for treating bone loss associated with hormone ablation therapy in men with prostate cancer and long-term systemic glucocorticoid therapy in adults.
Both biosimilars have demonstrated comparable quality, safety, and efficacy to the reference Denosumab product based on comprehensive clinical trial data. This approval from the EC follows a positive recommendation issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
JCR Pharmaceuticals Selected for Japan's Regenerative Medicine CDMO Subsidy Program
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been selected for the Ministry of Economy, Trade and Industry's 'Regenerative CDMO Subsidy' as of July 15, 2025. The subsidy will support facility upgrades and equipment installation to expand biomanufacturing capacity for regenerative, cell, and gene therapies. Project Overview 1) Project Title JCR Regenerative Medicine CDMO Enhancement 2) Description Building on its expertise in regenerative medicine, JCR will strengthen its biomanufacturing capability through facility upgrades and workforce training. 3) Period Approval date – December 31, 2027 Background and Rationale Since the 2015 approval of TEMCELL ® HS Inj., JCR has steadily built expertise in regenerative medicine while ensuring a stable, long-term product supply. The company is now developing an AAV gene therapy platform, JUST-AAV, based on its proprietary J-Brain Cargo ® technology for delivery across the blood-brain barrier. To leverage these assets as a development and manufacturing partner for regenerative medicine products, JCR applied for this government subsidy to support manufacturing-related capital investment. Looking Ahead With this subsidy, JCR will invest not only in its own pipeline but also in new partnerships, strengthen as its role in biomanufacturing in regenerative and gene/cell therapies. About the Regenerative CDMO Subsidy Program This subsidy program supports the development of domestic CDMO (Contract Development and Manufacturing Organization) facilities and talent to ensure Japan's capacity to manufacture regenerative, cell, and gene therapies. For details, visit: (Japanese only). About JUST-AAV JUST-AAV is a proprietary platform technology that utilizes modified adeno-associated virus (AAV) vectors. The technology entails insertion of miniaturized antibodies against receptors on selected tissues, organs or the blood-brain barrier onto the capsid surface, enhancing targeted delivery to those tissues and organs. Further capsid modifications minimize off-target effects and improve safety. The name is derived from ' J CR' ' U ltimate destination of organ' ' S afeguarding against off-target delivery' and ' T ransformative technology' reflecting its potential for broad application across various diseases. About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.
Business Wire
an hour ago
- Business Wire
NextGen Healthcare Chosen by Phoenix Heart to Optimize Financial Outcomes and Enhance Patient Experience
REMOTE-FIRST COMPANY/PHOENIX--(BUSINESS WIRE)--NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, has been selected by Phoenix Heart to improve workflows, deliver meaningful financial and operational analytics, and enable a better experience for patients, providers and staff. The NextGen Cardiology Suite, a specialty package that overlays the NextGen® Enterprise EHR (electronic health record), will reduce friction by supporting specialty-specific workflows. 'NextGen Healthcare understands our needs and shares our commitment to making healthcare as seamless as possible for providers, staff, and the communities we serve,' said Elizabeth Saylor, chief executive officer, Phoenix Heart Share Voted the state's #1 cardiology group for eight consecutive years in the annual The Best in Arizona Business poll, Phoenix Heart offers heart, vein, and vascular care across eight locations in the greater Phoenix region. Until now, staff at Phoenix Heart have relied on tedious manual processes to complete mission-critical workflows. NextGen® Enterprise PM (practice management), NextGen® Financial Analytics and NextGen® Operational Analytics will be integrated to simplify workflows while offering transparency, predictive analytics, and actionable insights. 'NextGen Healthcare understands our needs and shares our commitment to making healthcare as seamless as possible for providers, staff, and the communities we serve,' said Elizabeth Saylor, chief executive officer, Phoenix Heart. 'We're excited to work together to improve clinical, operational, and financial processes and continue raising the bar in cardiovascular care.' NextGen® Patient Engage powered by Luma will boost staff efficiency by equipping patients to complete pre-visit intake at their own convenience from their personal devices. The Instant Medical History enhancement will capture discrete data from patients during remote check-in and seamlessly deliver that information to the appropriate places in the system. NextGen® Automated Document Sharing will also automate outbound faxes and expedite the delivery of documents into patient portals—minimizing work for staff and making it easier for patients to quickly access information. 'Phoenix Heart has been leading the way in cardiovascular care in Arizona for over four decades,' said Srinivas (Sri) Velamoor, president and chief operating officer, NextGen Healthcare. 'We are privileged to support Phoenix Heart with the next stage of their growth journey and elevate the provider, staff, and patient experiences with specialty-specific solutions that reduce burdens and make healthcare delivery more intuitive.' To learn more about how NextGen Healthcare helps cardiology practices achieve their goals, visit About Phoenix Heart Voted No. 1 in cardiology groups by Ranking Arizona magazine's Best in AZ Businesses readers' poll, Phoenix Heart is the leading cardiology group in the greater Phoenix area. Phoenix Heart has eight offices, conveniently located in Glendale, Scottsdale, Avondale, Anthem, Black Canyon City, Buckeye, Cottonwood, and Laveen Village. Since its inception in 1981, Phoenix Heart has set the gold standard for cardiological care in Arizona and beyond. The cardiologists that make up the medical team at Phoenix Heart represent an incredibly diverse and elite background of training, skills, and specialties. They're committed to improving and enriching the lives and health of every patient they see and are consistently at the forefront of adopting the newest and best technologies to advance the health of their patients. About NextGen Healthcare NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology and data solutions. We are reimagining ambulatory healthcare with award-winning EHR, practice management and surround solutions that enable providers to deliver whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a relentless quest to achieve better healthcare outcomes for all. Learn more at and follow us on Facebook, X, LinkedIn, YouTube, and Instagram.
Business Wire
3 hours ago
- Business Wire
Royal Devon NHS selects Wolters Kluwer's UpToDate Enterprise Edition CDS solution
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health announced today that the Royal Devon University Healthcare NHS Foundation Trust, an organization providing acute, community and specialist services across North Devon, Mid Devon, East Devon and Exeter, is the first NHS Trust to adopt UpToDate ® Enterprise Edition, a market-leading clinical decision support (CDS) solution. The Trust includes two acute hospitals and 17 community hospitals with over 1,100 beds. 'Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,' said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. 'By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision-making, helping us to deliver the best possible care for all patients, and enabling our local population to stay well.' UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. Using its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities. 'We are pleased to be working with The Royal Devon University Healthcare NHS Foundation Trust on the roll out of UpToDate Enterprise Edition,' said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. 'This is an innovative solution designed for forward thinking healthcare systems that are focused on transforming care delivery through integrated workflows that provide unparalleled content and faster time to answers.' Delivering high quality, efficient healthcare services 'Providing access to an evidence-based CDS like UpToDate helps reduce variability in care, drive better patient outcomes and save clinician time through faster decision-making at the point-of-care,' Prof. Harris continued. 'Diagnosing quickly and treating appropriately with the help of CDS means better care, better patient outcomes, and better use of invaluable healthcare resources.' Over 100 independent studies of UpToDate associate the use of the resource with clinician time savings and improvements on key hospital quality and efficiency metrics such as length of stay, medical errors, and unnecessary diagnostic testing. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
